Literature DB >> 19571474

Children's toxicology from bench to bed--Liver Injury (3): Oxidative stress and anti-oxidant systems in liver of patients with Wilson disease.

Hironori Nagasaka1, Masaki Takayanagi, Hirokazu Tsukahara.   

Abstract

The role of oxidative stress in the pathogenesis of liver disease in Wilson disease (WD), a genetic disorder characterized by excess hepatic deposition of copper, which generates free radicals, remains unclear. This study investigates oxidative stress on the liver and hepatic anti-oxidant responses in WD using liver specimens from affected patients showing mild liver damage (group I, n = 3), moderate or greater liver damage (group II, n = 5) and fulminant hepatic failure (group III, n = 5), and from asymptomatic carriers (n = 2). Decreased ratios of reduced glutathione (GSH) to oxidized glutathione (GSSG) and increased thiobarbituric acid reactive substance (TBARS), a lipid peroxidation product, were found in every affected patient, especially in groups II and III patients. Activities and protein expressions of Mn-dependent superoxide dismutase (Mn-SOD), CuZn-SOD, and catalase were decreased in all patients, especially in group III patients. Glutathione peroxidase activity was decreased only in group III patients. Asymptomatic carriers without any clinical manifestations showed normal TBARS level and GSH/GSSG ratio with increases in both GSH and GSSG levels. Their CuZn-SOD, Mn-SOD and catalase activities were increased. These results suggest that excessive copper-derived oxidants contribute to development and progression of liver disease in WD.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19571474     DOI: 10.2131/jts.34.sp229

Source DB:  PubMed          Journal:  J Toxicol Sci        ISSN: 0388-1350            Impact factor:   2.196


  7 in total

1.  Decreased serum antioxidant capacity in patients with Wilson disease is associated with neurological symptoms.

Authors:  Radan Bruha; Libor Vitek; Zdenek Marecek; Lenka Pospisilova; Sona Nevsimalova; Pavel Martasek; Jaromir Petrtyl; Petr Urbanek; Alena Jiraskova; Ivana Malikova; Martin Haluzik; Peter Ferenci
Journal:  J Inherit Metab Dis       Date:  2011-12-03       Impact factor: 4.982

2.  In vitro to in vivo extrapolation and species response comparisons for drug-induced liver injury (DILI) using DILIsym™: a mechanistic, mathematical model of DILI.

Authors:  Brett A Howell; Yuching Yang; Rukmini Kumar; Jeffrey L Woodhead; Alison H Harrill; Harvey J Clewell; Melvin E Andersen; Scott Q Siler; Paul B Watkins
Journal:  J Pharmacokinet Pharmacodyn       Date:  2012-08-09       Impact factor: 2.745

3.  Clusterin (apolipoprotein J), a molecular chaperone that facilitates degradation of the copper-ATPases ATP7A and ATP7B.

Authors:  Stephanie Materia; Michael A Cater; Leo W J Klomp; Julian F B Mercer; Sharon La Fontaine
Journal:  J Biol Chem       Date:  2011-01-17       Impact factor: 5.157

Review 4.  Reactive oxygen species, vascular Noxs, and hypertension: focus on translational and clinical research.

Authors:  Augusto C Montezano; Rhian M Touyz
Journal:  Antioxid Redox Signal       Date:  2013-06-06       Impact factor: 8.401

5.  A Study on Apoptosis and Anti-apoptotic Status in Wilson Disease.

Authors:  J Kalita; V Kumar; U K Misra
Journal:  Mol Neurobiol       Date:  2015-12-08       Impact factor: 5.590

6.  Investigation of Dynamic Thiol/Disulfide Homeostasis and Nitrosative Stress in Patients with Wilson Disease.

Authors:  Emine Melis Yücel; Bugra Tolga Konduk; Ahmet Saracaloglu; Sezgin Barutçu; Seniz Demiryürek; Fatma Kaba; Belma Dogan Güngen; Abdullah Tuncay Demiryürek
Journal:  Turk J Gastroenterol       Date:  2021-09       Impact factor: 1.555

7.  Analyzing the Mechanisms Behind Macrolide Antibiotic-Induced Liver Injury Using Quantitative Systems Toxicology Modeling.

Authors:  Jeffrey L Woodhead; Kyunghee Yang; David Oldach; Chris MacLauchlin; Prabhavathi Fernandes; Paul B Watkins; Scott Q Siler; Brett A Howell
Journal:  Pharm Res       Date:  2019-02-07       Impact factor: 4.200

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.